top of page

Market Access

eSYS provides end-to-end market access support, including economic modelling, Health Technology Assessment (HTA) submissions, literature reviews, budget impact analysis, policy strategy, and real-world evidence. Our work aligns with payer expectations in Australia, Switzerland, and Singapore

Operating Room

Services

Economic Modelling
Real World Evidence
Budget Impact Analysis
Policy Shaping

Featured Project

Calcitonin Gene-related Peptide Antagonists for the Prevention of Migraine in Switzerland
Swiss Federal Office of Public Heath
07/22-04/23
Europe
The Royal Australasian College of Surgeons with Ross McLeod, assessed CGRP antagonists for migraine in Switzerland. Results showed superior effectiveness and tolerability over standard care, with favorable cost-effectiveness in select patients. However, high budget impact may warrant targeted reimbursement to ensure healthcare system sustainability

Completed Market Access Projects

Treatment of Hypercholesterolemia and Hyperlipidemia with Ezetimibe-containing medicines in Switzerland

Switzerland

05/21-02/23

Image by Javi Hoffens
Swiss Federal Office of Public Health

The aim of the Health Technology Assessment (HTA) conducted with the Royal Australasian College of Surgeons was to evaluate the efficacy, safety, cost-effectiveness, and budgetary impact of ezetimibe-containing medicines compared to statins or fenofibrate in patients with hypercholesterolaemia or mixed/combined hyperlipidaemia. https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/ezetimib.html


Assessment of Deep Brain Stimulation of the Thalamus for the Treatment of Severe Refractory Epilepsy for MSAC in Australia

Australia

05/21-09/21

Image by Javi Hoffens
Royal Australasian College of Surgeons

Deep brain stimulation delivers electrical impulses to a key central location deep in the brain, suppressing the bursts of epileptic discharges that characterise seizures. Ross was contracted to undertake economic modelling and budget impact assessment for MSAC assessment.

Vertebroplasty or Kyphoplasty in Patients with Symptomatic Osteoporotic Vertebral Compression Fractures

Switzerland

11/20-05/21

Image by Javi Hoffens
Swiss Federal Office of Public Health

The objective of this HTA conducted with the Royal Australasian College of Surgeons was to evaluate the efficacy, safety, cost-effectiveness, and budgetary impact of percutaneous vertebroplasty and percutaneous balloon kyphoplasty in patients with symptomatic osteoporotic vertebral compression fractures unresponsive to non-surgical treatment. https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/vertebroplastie_kyphoplastie.html

Evaluating Reimbursement Dossiers for Australian Pharmaceutical Benefits Advisory Committee (PBAC)

Australia

10/16-11/20

Image by Javi Hoffens
Macquarie University Centre for the Health Economy

Health Technology Assessment (HTA) dossiers submitted for local reimbursement and pricing decisions to the Australian Pharmaceutical Benefits Advisory Committee (PBAC) were evaluated in collaboration with a cross-functional team. The clinical and economic evidence presented in the submissions was analyzed.

Long-term Physiotherapy in Patients after Stroke, with Multiple Sclerosis, or with Parkinson’s disease

Switzerland

03/21-09/21

Image by Javi Hoffens
Swiss Federal Office of Public Health

Some patients after stroke, with multiple sclerosis (MS), or with Parkinson’s disease currently receive physiotherapy over a lengthy period (more than 36 physiotherapy sessions per year). The question arises as to whether long-term physiotherapy for these patients’ additional benefits has compared with those receiving short-term physiotherapy. The aim of the HTA undertaken with the College of Surgeons was to assess the efficacy, safety, cost-effectiveness, and budgetary impact of long-term physiotherapy for patients after stroke, with MS or Parkinson’s disease. https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/langzeitphysiotherapie.html

Gastrointestinal Endoscopic Mucosal Resection (EMR) Assessment for MSAC

Australia

11/19-1/20

Image by Javi Hoffens
Royal Australasian College of Surgeons

Gastrointestinal Endoscopic Mucosal Resection (EMR) is a procedure used to remove early-stage cancers and precancerous growths from the digestive tract lining.  It is considered a less invasive alternative to surgery for conditions like Barrett's esophagus and colorectal cancer. The Medicare Benefits Schedule Review Taskforce proposed new funding options for EMR, emphasizing its safety, effectiveness, and potential benefits over traditional surgery. A Markov model and budget impact analysis was undertaken prior to listing of the procedure on the MBS

bottom of page